NCT03420469View on ClinicalTrials.gov

Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 5, 2018

Primary Completion Date

May 1, 2019

Study Completion Date

May 1, 2019

Conditions
Adverse Effect of Drug Therapy Metabolism Medications (Diagnosis)
Interventions
DRUG

Bupropion

Phase 1: Baseline CYP2D6 activity, using dextromethorphan (30 mg single dose PO) as a probe drug Phase 2: Single dose bupropion pharmacokinetics and its effect on CYP2D6 activity (determined by dextromethorphan 30 mg single dose PO) Phase 3: Steady state disposition of bupropion and its interaction with CYP2D6 activity (30 mg single dose PO)

Trial Locations (1)

46202

Indiana Clinical Research Center (ICRC), Indianapolis

All Listed Sponsors
collaborator

National Institute of General Medical Sciences (NIGMS)

NIH

lead

Indiana University

OTHER

NCT03420469 - Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers | Biotech Hunter | Biotech Hunter